NASDAQHealth CareMedical - Healthcare Information ServicesSnapshot 2026-11-04
The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.
Next-FY EPS estimate change · 30 days
Matching fiscal periods, usable estimates and at least one analyst are required.
One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.
The calculation requires same-period, same-provider snapshots, positive EPS, at least one analyst and a baseline within three days of the requested lookback.
The EPS and P/E reference is not available for ONMD yet.
| Measure / period | Management expectations | Analyst expectations |
|---|
Management figures unavailable.
Current consensus figures unavailable.
Three published thesis conditions, with dated milestones shown separately.
| Key Factor | Why It Matters | Current Status | Break Condition | Latest Evidence |
|---|---|---|---|---|
Operating losses improve toward -$2.55 million or better | A primary condition in OneMedNet Corp's published investment case. The stated target is Operating loss <= -$2.55 million. | Broken | Operating loss worsens beyond -$2.55 million next quarter | Operating income: $-2.261M FY2026-Q2; GAAP. Published target: Operating loss <= -$2.55 million. The stored target says 2026-Q1; this source reports FY2026-Q2. Fiscal/calendar alignment needs review. Aug 14, 2026-2,261,000 USD · source valueLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Compare these dated observations with the operating requirements above
Comparable estimate history is unavailable.
Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.
Compare required revenue and earningsMonthly analyst history is unavailable.
Recent actions · Oct 6–Nov 4 · 0 recorded
The evidence, the remaining questions, and what comes next
No recovery evidence is reported in the available driver assessments.
Nov 13, 2026
Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.
Review earningsObserved price history; separate from operating scenarios
The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.
This is a speculative turnaround, meaning the thesis depends on a struggling business improving its performance. The thesis is in a watch state: revenue has grown and operating losses have narrowed, but the company remains loss-making and its recent financial performance is below its industry cohort.
The valuation model shows a premium versus peers, with low confidence and an expectations gap tied to potential optionality, or possible future sources of value. The evidence does not show that this premium is supported by strong current earnings, since ONMD is still loss-making.
Over the multi-year view, revenue growth and narrower operating losses provide signs of gradual progress, while management has repeatedly named reducing losses as a priority. Near term, results remain below the industry cohort, and the business faces high risk; a reverse stock split addressed Nasdaq’s minimum bid requirement, while an equity agreement allows up to $25 million in stock sales to support capital needs.
The thesis depends on whether revenue growth continues and operating losses keep narrowing. Near term, weakening jobs data could weigh on cyclical healthcare names, while stronger results and guidance from sector bellwethers could sustain sector momentum; misses or weaker guidance could remove that support.
Over the next 1 to 3 years, ONMD’s long-term thesis rests on continued operating improvement and adequate capital, but losses, high risk, and a peer valuation premium leave the case fragile. Not investment advice.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Stated in a supplied disclosure. Management reported: “With a network spanning more than 2,300 sites and encompassing over 90 million patient journeys and 270 million studies, OneMedNet serves life sciences companies, medical device manufacturers, AI developers, and other innovators seeking high-quality, compliant healthcare data.” Operating income was $-2.261 million in 2026-Q2.
Delivery assessment Nov 4, 2026Maintain access to capital via equity agreements | A supporting condition in OneMedNet Corp's published investment case. The stated target is Active standby equity purchase agreement. | Intact | Equity funding agreement is terminated or fails to close | SEPA active ($25M) vs target: Active standby equity purchase agreement OneMedNet entered a $25M SEPA with Yorkville on July 1, 2026, and a director invested $750,001 in October 2026. Nov 4, 2026Last status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Revenue stabilizes near $96,000 or higher | A primary condition in OneMedNet Corp's published investment case. The stated target is Revenue >= $96,000. | Broken | Revenue falls below $96,000 next quarter | Revenue: $292,000 FY2026-Q2; GAAP. Published target: Revenue >= $96,000. The stored target says 2026-Q1; this source reports FY2026-Q2. Fiscal/calendar alignment needs review. Aug 14, 2026292,000 USD · source valueLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management contextStated in a supplied disclosure. Management reported: “With a network spanning more than 2,300 sites and encompassing over 90 million patient journeys and 270 million studies, OneMedNet serves life sciences companies, medical device manufacturers, AI developers, and other innovators seeking high-quality, compliant healthcare data.” Operating income was $-2.261 million in 2026-Q2. Delivery assessment Nov 4, 2026 |
Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.
Individual price-target observations are unavailable.
0 raises · 0 cuts · 0 unchanged · 0 without a comparable prior
Oct 6, 2026–Nov 4, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.
2 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.
The dated weekly assessment and its assumptions are available in Read detailed Outlook.